The GLP-1 Aftershock Effects

What 100+ obesity brand stakeholders say is changing and where pharma marketing goes next

GLP-1s aren’t just a “hot moment” in obesity. They’re stress-testing the entire commercial model. In this webinar we’ll start with a rapid pulse-check from BGBx’s stakeholder research: what’s keeping obesity brand teams awake (the real blockers, not the polite ones), what they’re prioritising over the next 12–18 months, and where they’re betting on omnichannel and AI to move faster without breaking compliance.

Watch the webinar recording now!